Clinical Trial

A Study of Eloralintide (LY3841136) and Eloralintide With Tirzepatide in Participants With Overweight or Obesity

Completed Phase 1
View on ClinicalTrials.gov →
Summary
The purpose of this study is to evaluate how well eloralintide and eloralintide with tirzepatide is tolerated and what side effects may occur in participants with overweight or obesity. The study drug will be administered subcutaneously (SC) (under the skin). Blood tests will be performed to check how much eloralintide and eloralintide with tirzepatide get into the bloodstream and how long it takes the body to eliminate it. There will be 6 cohorts. The study will last up to approximately 26 weeks, excluding screening for Cohorts A and B, 11 weeks for Cohorts C and D, and 12 weeks for Cohorts E and F.
Protocol Amendment History 9 amendments
This ClinicalTrials.gov record has been amended 9 times since 2025-04-01; most recent amendment 2026-01-29.
Status change: Active, Not Recruiting → Completed 2026-01-16
Status change: Recruiting → Active, Not Recruiting 2025-11-21
Status change: Not Yet Recruiting → Recruiting 2025-05-23
Trial Details
NCT Number NCT06916065
Lead Sponsor Eli Lilly and Company
Conditions Overweight, Obesity
Enrollment 188 participants
Start Date 2025-04-09
Primary Completion 2026-01-19 (estimated)
Study Completion 2026-01-19 (estimated)
Updated on ClinicalTrials.gov 2026-01-30